These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 30726846)
1. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Berezowsky A; Pardo J; Ben-Zion M; Wiznitzer A; Aviram A Fetal Diagn Ther; 2019; 46(3):187-192. PubMed ID: 30726846 [TBL] [Abstract][Full Text] [Related]
2. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251 [TBL] [Abstract][Full Text] [Related]
3. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. Thompson O; Otigbah C; Nnochiri A; Sumithran E; Spencer K BJOG; 2015 Sep; 122(10):1370-6. PubMed ID: 25639820 [TBL] [Abstract][Full Text] [Related]
5. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-HCG. Chen Y; Huang J; Mei J Clin Biochem; 2019 Jul; 69():21-25. PubMed ID: 31152694 [TBL] [Abstract][Full Text] [Related]
6. [The value of maternal first and second trimester serum data of β-hCG, PAPP-A, AFP and uE3 in the prediction of preeclampsia]. Gu W; Lin J; Hou Y Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):101-7. PubMed ID: 25877605 [TBL] [Abstract][Full Text] [Related]
7. Maternal serum second trimester AFP and hCG in pregnancies with placenta previa. Heikkilä A; Heinonen S; Kirkinen P Prenat Diagn; 2000 Feb; 20(2):100-2. PubMed ID: 10694682 [TBL] [Abstract][Full Text] [Related]
8. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes]. Hu Z; Liu X; Li L; Jia C; Li D; Liu R Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246 [TBL] [Abstract][Full Text] [Related]
9. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. Tancrède S; Bujold E; Giguère Y; Renald MH; Girouard J; Forest JC J Obstet Gynaecol Can; 2015 Feb; 37(2):111-6. PubMed ID: 25767942 [TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Second-Trimester Biomarkers and Maternal Features for Adverse Pregnancy Outcomes. Yefet E; Kuzmin O; Schwartz N; Basson F; Nachum Z Fetal Diagn Ther; 2017; 42(4):285-293. PubMed ID: 28395283 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18. Chen Y; Chen Y; Ning W; Zhang W; Li L; Wang X; Yin Y; Zhang H Sci Rep; 2022 Aug; 12(1):13605. PubMed ID: 35948592 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of specific proteins of pregnancy in women with a uterine scar and placenta accreta.]. Borovkov VA; Igitova MB; Korenovskiy YV; Dudareva YA Klin Lab Diagn; 2020; 65(6):353-357. PubMed ID: 32459893 [TBL] [Abstract][Full Text] [Related]
14. Elevated second-trimester maternal serum β-human chorionic gonadotropin and amniotic fluid alpha-fetoprotein as indicators of adverse obstetric outcomes in fetal Turner syndrome. Alvarez-Nava F; Soto M; Lanes R; Pons H; Morales-Machin A; Bracho A J Obstet Gynaecol Res; 2015 Dec; 41(12):1891-8. PubMed ID: 26369382 [TBL] [Abstract][Full Text] [Related]
16. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738 [TBL] [Abstract][Full Text] [Related]
17. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832 [TBL] [Abstract][Full Text] [Related]
18. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age. Chen Y; Wang X; Li L; Lu S; Zhang Z BMC Pregnancy Childbirth; 2020 Dec; 20(1):776. PubMed ID: 33317474 [TBL] [Abstract][Full Text] [Related]
19. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects. Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ Prenat Diagn; 2009 Jun; 29(6):570-7. PubMed ID: 19266536 [TBL] [Abstract][Full Text] [Related]
20. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Audibert F; Benchimol Y; Benattar C; Champagne C; Frydman R Fetal Diagn Ther; 2005; 20(1):48-53. PubMed ID: 15608460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]